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1. Introduction 
ESBL and AmpC producing E. coli have 
emerged and spread in in food producing 
animals. The emergence of this potential 
zoonotic pathogen in animals has raised the 
concerns of potential transmission to humans 
from the animal reservoirs with consequences 
on Public Health. In 2013, the European 
Commission (EC) took the decision of including 
the isolation of ESBL and AmpC producing E. 
coli as mandatory parts of the EU monitoring to 
be started during 2015 and focusing firstly on 
cattle and swine samples, including meat  as 
representative of food samples and caecal 
content as representative of samples taken 
from the animal population. Thus, this 
screening has been started in the beginning of 
2015 in the EU Member States and affiliated 
countries according to a common protocol 
defined by the EC and validated by the 
European Union Reference Laboratory for 
Antimicrobial Resistance (EURL-AR before the 
specific monitoring was implemented at MS 
(EURL-AR, 2014). 
The EURL-AR took part in the development and 
support of the laboratories for this task by 
providing the protocol for testing and assistance 
in setting up the methods for isolation, 
identification, and typing of ESBL/AmpC (and 
carbapenemase) producing E. coli isolates. 
Additionally, the EURL-AR provided training in 
the specific methods at a training course 
organized in Lyngby in the autumn of 2014. 
In October 2015, the EURL-AR launched, in 
addition to the External Quality Assurance 
System (EQAS) already performed, a matrix 
based specific EQAS to enhance the capacity 
of the laboratories in ESBL/AmpC producing E. 
coli isolation, identification and antimicrobial 
susceptibility testing (AST). This EQAS aimed 
towards identification of potential problems and 
identification of focus areas for future 
training/education that might improve data 
quality in future monitoring. 
Before November 2015 several preliminary 
studies were conducted to prepare for the 
launch of this EQAS, using meat samples and 
caecal content matrices spiked with strains of 
interest or naturally positive.  
In November 2015, we launched the first EQAS 
performed on ESBL/AmpC producing E. coli 
isolation, identification and AST in matrices of 
meat and caecal samples (EQAS matrix). This 
trial included isolation steps, confirmation of the 
ID as E. coli, MIC testing and confirmation of 
ESBL/AmpC phenotypes and as these are part 
of the mandatory tasks for confirmation of ESBL 
/AmpC strains the conclusions drawn were 
included in the trials. At the present time the 
detection of carbapenemases is not 
compulsory, and the additional isolation 
procedures for carbapenemase isolation were 
not included in the EQAS trial.  
Starting in January 2015, the laboratories 
should have implemented the methods and 
have started the monitoring on meat and caecal 
samples from porcine and bovine origin. 
Therefore the methods should have been 
implemented and validated at the NRL’s before 
this EQAS. The participation in this EQAS may 
be used to assess the quality of data provided 
to EFSA, retrospectively. 
No thresholds have been set in advance to 
evaluate the performance of the participating 
laboratories, nor classify the results of this 
EQAS, as there were issues related to stability 
which have caused deviations.  
The EQAS was organized by the National Food 
Institute (DTU Food), Kgs. Lyngby, Denmark. 
The data in this report are presented with 
laboratory codes. A laboratory code is known 
only by the individual laboratory, whereas the 
entire list of laboratories and their codes is 
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confidential and known only by relevant 
representatives of the EURL-AR and the EU 
Commission. All conclusions are public.  
The technical advisory group for the EURL-AR 
EQAS scheme consists of competent 
representatives from all National Reference 
Laboratories for Antimicrobial Resistance 
(NRLs-AR), who meets annually at the EURL-
AR workshop. 
2. Materials and Methods  
2.1 Participants in EQAS 2015 
A pre-notification (App. 1), inviting the 
participants to the matrix EQAS 2015 was 
issued by e-mail to the EURL-AR network on 
the 11th  of September 2015 to the NRL-AR’s. 
All participants were included in a participant list 
(App. 2) before the preparation and shipping of 
the samples. Participation was free of charge 
but each laboratory was expected to cover 
expenses associated with their own analysis.  
2.2 Preparation of samples  
Eight samples were prepared and dispatched 
for isolation of ESBL or AmpC E. coli, including 
identification, and AST of the obtained isolates. 
The samples included were both meat and 
caecal samples and were either artificially 
prepared to contain the test strains or 
unmodified.  
The meat used to prepare the samples was 
minced beef with 8-15% fat acquired in local 
supermarkets (at least three batches were 
bought in sufficient amount for covering both 
the pre-tests and preparation of the samples). 
The meat was pretested using the official 
method for selective isolation of E. coli 
producing ESBL or AmpC to make sure the 
batch used was negative for ESBL or AmpC 
producing E. coli but contained background 
flora. The chosen batch should contain average 
E. coli background but not ESBL or AmpC 
suspected colonies. A batch fulfilling these 
criteria was chosen for preparation of aliquots 
of 25 g of meat that were either directly used as 
blank samples or spiked as follows. 
The test isolates used in the spiking of meat 
samples within the EQAS matrix 2015 were 
prepared in advance and subcultured the day 
before sample preparation. For the sample 
preparation and standardization of the spiking, 
suspensions equal to McFarland 0.5 were 
prepared in saline tubes with the relevant 
isolates to contain about 108 CFU/mL and 
counted using viable counts of serial dilutions 
on agar. The standardized suspensions were 
further diluted in tenfold dilution row and the 
meat samples (25 g) were spiked with 25 µl of 
the chosen dilutions. The final inoculum was 
expected to be about 103 CFU/g of meat, for 
samples M-1.1, M-1.2, and M-1.5, where the 
sample M-1.4 was spiked with a lower amount 
of about 10 CFU/g of the test strain, and the 
sample M-1.3 was left as blank, containing only 
the background flora present in the meat. The 
sample M-1.5 was spiked as mentioned above, 
however with a susceptible strain (ATCC 
25922) and therefore expected to be negative. 
For the caecal samples, the tests performed in 
the preparation phase showed challenges in 
keeping the strains viable and stable along 
time, therefore we opted for natural samples. 
One slaughterhouse provided us with 10-15 
caecal samples from pig origin, each batch in 
sufficient amount so that the samples could be 
prepared from one of these single batches of 
matrix. The samples were tested individually 
using the official selective isolation protocol for 
ESBL and AmpC testing. Furthermore, the 
samples were tested to approximate E. coli 
counts using spot method plated on Mac 
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Conkey agar with and without cefotaxime 1 mg 
/L. The one negative caecal sample was 
chosen to prepare the blank sample (EURL-M-
1.6) and two positive samples were chosen to 
prepare positive samples (EURL-M-1.7 and 
1.8). However, during the last part of the 
preparation one of the isolates obtained from 
one of the positive samples (EURL-M-1.7) 
failed to grow on the MIC panels. We re-
evaluated the possibilities and prepared a 
spiked caecal sample using negative caecal 
material and spiked with one isolate which was 
recently obtained from a pig caecal sample and 
this solution seemed to be more stable. 
However to avoid issues with stability the 
spiking was performed with a larger inoculum at 
105 CFU/g. This sample was prepared and 
coded as EURL-M-1.7. The latter sample 
(EURL M 1.8) was a naturally positive sample 
showing an AmpC AST profile that had shown 
good stability up to 2 weeks after shipment. The 
minimal inhibitory concentrations (MIC) of the 
selected antimicrobial panels were determined 
using  microdilution methods at two different 
occasions (firstly, on the strains used for spiking 
during the preparation work and again from the 
isolates obtained in the homogeneity testing 
after sample preparation) to generate expected 
results (App 3).and the genes identified in the 
spiking isolates were detected using PCR on 
the isolates obtained from the isolation 
procedure performed on the samples.  
Stability testing was performed for following up 
on the stability of the samples after shipping. 
The test was performed on one set of the eight 
samples and in four occasions after shipment 
(during two weeks). In this period the meat 
samples were kept frozen and the caecal 
samples were kept at cooling temperature at 
4°C. 
 
2.3 Isolation and identification of 
ESBL or AmpC producing E. coli 
from meat or caecal samples  
The official protocols for selective isolation and 
identification of the ESBL or AmpC E. coli 
isolates contained in swab samples were 
available on the EURL website, 
http://www.eurl-ar.eu (App. 4a and 4b). For the 
identification of E. coli species different 
methods were allowed as these are not 
specified in the regulation. The description of 
the method used for selective isolation and 
species identification were requested as part of 
the methods sheet under the database upload 
system. 
2.4 Antimicrobial susceptibility 
testing 
The panels of antimicrobials recommended for 
AST in this trial are those included in the EU 
regulation for Antimicrobial susceptibility 
monitoring at EU level - EC 652/2013 (Table 1). 
Guidelines for performing the antimicrobial 
susceptibility testing using dilution methods 
were set according to the Clinical and 
Laboratory Standards Institute (CLSI) document 
– M7-A10 (2015) “Methods for Dilution 
Antimicrobial Susceptibility Tests for Bacteria 
That Grow Aerobically; Approved Standard - 
tenth Edition”” and whenever commercial 
methods were used, the guidelines of the 
manufacturer were followed. 
MIC results were interpreted by using EUCAST 
epidemiological cut-off values 
(www.eucast.org), as included in the regulation 
referred above or as recommended by EFSA 
and described in the EQAS protocol (App. 4). 
Results of the ESBL confirmatory testing were 
interpreted according to the recommendations 
by EFSA and as referred in the regulation, 
using MIC testing by the second panel of 
antimicrobials, which is intended to be tested 
every time a strain was found resistant to either 
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cefotaxime, ceftazidime or meropenem in the 
first E. coli panel and interpreted according to 
the protocol, enabling to conclude on the 
strain’s presumptive ESBL/AmpC or 
carbapenemase phenotype. 
2.5 Distribution 
For keeping the stability the meat samples were 
frozen at -80°C and kept at this temperature 
after preparation and until shipment. The caecal 
samples were sent short after reception and pre 
testing, and therefore kept at refrigerator 
temperature until shipment. At the day of 
shipment, the samples were tightly packed in 
thermoboxes with cooling elements frozen at -
80°C. The parcels contained the eight samples 
in tubes, and additional one tube containing a 
thermologger to register the temperature at 15 
min intervals during transit. Furthermore, the 
parcel contained a welcome letter containing 
the login and password to the web based 
database for the data upload and a labelled 
envelope for returning the thermologger to the 
EURL-AR.  
The protocol for the EQAS with detailed 
instructions and respective test forms were 
made available online on the EURL-AR 
website, http://www.eurl-ar.eu, before 
launching this EQAS. 
The thermoboxes used for the shipment of 
samples were enclosed in double pack 
containers and sent to the selected laboratories 
according to the International Air Transport 
Association (IATA) regulations as “Biological 
Substance category B” classified UN3373. The 
parcels were dispatched from DTU-Food 
November 2nd , 2015. 
The laboratories were instructed to download 
the protocol and test forms (App. 4 and 5), 
from http://www.eurl-ar.eu and to process the 
samples and the analysis following the EU 
protocol for selective isolation of ESBL and 
AmpC presumptive E. coli from either meat or 
caecal samples, exactly as they would 
normally proceed in the EFSA monitoring, 
and to follow the instructions given for upload 
of the data in the web based database. 
Furthermore, the test forms contained the 
schemes to collect the data to be uploaded 
Table 1. Panel of antimicrobials recommended for susceptibility testing of bacteria included in this EQAS 2015 component 
Escherichia coli Escherichia coli 
2nd panel 
Ampicillin, AMP Cefepime, FEP 
Azithromycin, AZI Cefotaxime + clavulanic acid (F/C) 
Cefotaxime, FOT Cefotaxime, FOT 
Ceftazidime, TAZ Cefoxitin, FOX 
Chloramphenicol, CHL Ceftazidime, TAZ 
Ciprofloxacin, CIP Ceftazidime+ clavulanic acid (T/C) 
Colistin, COL Ertapenem, ETP 
Gentamicin, GEN Imipenem, IMI 
Meropenem, MERO Meropenem, MERO 
Nalidixic acid, NAL Temocillin, TRM 
Sulfamethoxazole, SMX  
Tetracycline, TET  
Tigecycline, TGC  
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on the database, which was designed and 
prepared for this EQAS and opened shortly 
after sample shipment and until the deadline 
(App 4 and 5). 
After completion of the tests, the laboratories 
were requested to enter the obtained results 
into the electronic sheet in the EURL-AR web 
based database through a secured individual 
login (App 5). The database was activated on 
the 19th November, 2015 and closed 
December 9th  2015. 
For the first part of the results of the selective 
isolation procedure, the samples were 
categorised as positive or negative and this 
qualitative result was registered in the 
database. Additionally, the results of 
susceptibility testing using both MIC panels 
were uploaded for the isolates obtained, 
similarly to the E. coli AST EQAS, including 
the read values of MIC and their 
interpretations. As a conclusion of the 
susceptibility testing, the participants were 
asked to classify the isolates obtained 
according to the defined EFSA criteria 
regarding the phenotypes observed. 
After the deadline, the qualitative results 
indicating if the samples were positive or 
negative, as well as the interpretations of the 
susceptibility tests performed, and the 
conclusion on the observed E. coli 
phenotypes were evaluated against the 
expected results and scored as correct or 
incorrect, without further classification of the 
deviation.  
 
 
3. Results 
A total of 35 laboratories participated in the 
EQAS; including 31 labs representing NRLs 
from all 28 MS (please note that for three MS 
the samples were divided by type between two 
laboratories), and laboratories from Norway, 
Switzerland and Iceland responded to the pre-
notification and were additionally enrolled in the 
EQAS. One additional non-NRL from EU was 
enrolled and provided results but was not 
included further in the report. For more 
information on the countries participating 
consult the map below (Figure 1).  
Two laboratories (#40 and #34) received their 
set of samples at a later date (17th November 
2015) due to issues with the shipment of 
samples and therefore their results were not 
included in the report as the stability could be 
affected, and the samples had been kept for a 
longer time in storage compared to the EURL-
AR premises. 
When the deadline for submitting results was 
reached, all enrolled laboratories had uploaded 
data for the respective samples tested, thus all 
represented countries had one complete set of 
data.  
The participating laboratories have, as 
requested, returned the termologgers to the 
EURL (here the registration of the temperature 
was extracted and read to provide the 
temperature ranges along the shipment and at 
sample reception/opening. Furthermore, the 
participants were requested to provide more 
information in a small introductory questionnaire 
on the webpage, including details on sample 
reception (measured temperature and time), the 
monitoring activities (samples tested and 
amounts), and the methods used in their 
laboratory. 
The temperature data was analysed at the 
EURL and showed a range of temperatures 
between -5°C and 8°C for measures taken by 
the participants, and -1°C and 4°C, when 
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inferred from the temperature at opening time 
from the thermologger registration (Figure 2). 
This showed that the samples were expected to 
be in good conditions for testing at opening of 
the samples. In only one case (#Lab 39 ) it was 
not possible to correctly estimate the 
temperature at sample processing as the 
participants reported that the sample was not 
processed immediately, but kept in refrigeration 
from reception (5th November) to the start of 
processing of samples 15th November. 
3.1 Methods used by EQAS-
participants 
Of the 32 laboratories submitting results all 
(100%) of the laboratories participated in the 
ESBL and AmpC isolation and identification 
parts as well as the susceptibility testing parts. 
The number of tests uploaded was rather 
diverse, depending on both how many samples 
were tested in the laboratory in question (as 
some only tested meat or caecal samples and 
some tested both (three to eight samples)), and 
how many of these were found positive. The 
number of tests performed ranged from 20 to 
 
Figure 1. Participating countries in EQAS matrix 2015. 
 
Figure 2. Temperatures measured at reception/opening measured by own measurement and 
temperature logger in parcels EQAS matrix 2015. 
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105 tests per participant. 
Information on the methods used for isolation, 
identification and typing was collected from the 
participants through the database.  
Most laboratories (n=30) reported that isolation 
has been performed exactly according to the 
protocol provided by the EURL-AR for this 
EQAS and any changes in media, 
concentrations of antibiotics, etc. were referred. 
The differences reported by some laboratories 
from the method described in the original 
protocol were: incubation at 41.5°C and 20h 
incubation for the selective plates (Lab #36); 
and the use of 0.8% cefotaxime for 
supplementing the selective plates (Lab #58). 
One participant did not provide data (Lab #60) 
The species confirmation testing was performed 
in the majority of the laboratories using 
biochemical tests (n=13) followed by 
chromogenic agar plating (n=8), MALDI TOF 
(n=8), and PCR (n=3). 
The MIC was as for the AST EQAS only done 
using the antimicrobials and ranges regulated 
under the EU Commission regulation 652/2013. 
3.2 ESBL /AmpC producing E. coli 
isolation and identification 
A total of 232 tests results were uploaded. 
Twenty six of the participating laboratories have 
reported results for all the eight samples sent. 
Three laboratories reported only the five results 
for the meat samples (Labs #13, #38, and #41) 
and three laboratories reported the results for 
the three caecal samples (Labs #16, #32, and 
#58).  
All in all 204 tests were correct, corresponding 
to 87.9% of correct results (and 12.1% 
deviations). From the 87 samples expected to 
be negative 97.7% (n=85) were correctly 
assigned, and the remaining two were found 
false positive. Regarding the samples expected 
to be found positive, 82.1% were correctly 
found positive (119 out of 145). When looking at 
the analysis per sample type we observe that 
among the meat samples 93.1% (135 out of 
145) samples were correctly tested whereas 
among the caecal samples 79.3% ( 69 out of 
87) samples were found correctly assigned 
qualitatively (Table 2).  
Table2. The overall performance of ESBL/AmpC isolation and identification, 2015. 
Isolation of ESBL /AMPC from samples  Correctly classified samples 
Number of performed tests Number of correct tests N(%) 
N % N % 
232 100 204 87.9 
Number of expected negative tests Number of correctly identified negative tests 
N % N % 
87 37.5 85 97.7 
Number of expected positive tests Number of correctly identified positive tests 
N % N % 
145 62.5 119 82.1 
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As described above, most deviations were 
caused by a lack of sensitivity of the methods 
used, leading to false negative results in 29 
samples in total, whereas only four false 
positives were observed.  
Also from the analysis above we can observe 
that the results were better for meat samples 
than for the caecal samples which might be due 
to issues with stability, especially regarding 
sample M-1.8. 
The results per sample show that most 
deviations were observed for sample EURL-M-
1.8 which caused 18 deviations and therefore a 
total of 62.1% deviating results. This was 
probably due to stability or eventual uneven 
homogeneity of this particular caecal sample 
which might have caused some of the negative 
results in the isolation of the resistant strain 
which was present naturally in this sample. The 
remaining samples had deviation percentages 
around or below 10%, with sample M-1.1 and 
M-1.4 highest at 10.3% (3 deviations each), 1.2, 
at 6.9% (2 deviations), and the remaining 
samples had less than 5% deviations. As 
observed above the highest deviation 
percentages were observed for the positive 
samples, especially for samples M-1.1 and M-
1.4 which were expected to be positive as and 
ESBL producing strain had been included in 
these samples, however in different amounts. 
M-1.1 was inoculated with a high amount at 
around 103 CFU/g whereas 1.4 had been spiked 
with circa 10 CFU/g of the same strain. This 
strain had the particularity of growing as white 
colonies on TBX agar even though it was an E. 
coli strain and therefore using this type of 
chromogenic agar as identification method was 
not appropriate for this particular strain, which 
might have influenced the result for some of the 
participants, showing the need to use other ID 
methods or supplement with additional tests, for 
identifying this type of strains (Figure 3). 
When analysing the results per laboratory three 
participants (Labs #6, #18, and #20) had three 
deviations, out of the eight samples tested, 
accounting for 37.5% deviations (all three labs 
had a deviation in the M-1.8 sample and two 
additional samples). One participant among the 
three laboratories only analysing the caecal 
samples (#16) had 33.3% deviation due to one 
deviation on the sample M-1.8 while the other 
two laboratories analysing only the ceacal 
samples had no deviations. Two participants 
(Lab #30 and #39) had two deviations each 
(one on sample 1.8 and one additional) 
obtaining 25% deviations. Fourteen participants  
had one deviation only and the remaining 12 
laboratories did not have any deviation in this 
qualitative exercise (Figure 4). Further 
communication with Labs #6 and #18 showed 
that they both experienced the same issue, as 
they actually had isolated a suspected isolate 
from samples M-1.1 and M.1.4 but did not 
confirm the ID as E. coli due to the use of 
chromogenic agar (TBX), which did not show 
the expected blue colour as this particular strain 
included in both of the samples appeared to 
have white colonies on this type of agar. 
Therefore, these labs have been advised to use 
different ID tests as alternative or complement 
to the use of chromogenic agar for species ID. 
3.3 Antimicrobial susceptibility 
testing 
A total of 2473 tests results were uploaded and 
2371 (95.9%) of these were correct. All 32 labs 
have uploaded a variable number of results, 
depending on the samples found positive and 
isolates tested in one or both panels, ranging 
from 20 to 105 test results per participant. 
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When analysing the results per antimicrobial we 
observed that the results for ertapenem showed 
the highest deviation percentage, at around 
39.8% followed by ceftazidime and cefoxitin 
with 8.4% and 7.7%, respectively. The 
remaining antimicrobials showed deviation 
levels below 5% (Figure 5). This might be 
related to results lying close to the breakpoint 
for these particular drugs, and issues related to 
permeability causing relatively high MIC to 
ertapenem. 
The analysis performed per sample indicates 
that the highest deviation level (6.8%) was 
observed for sample M-1.8, caused by 15 
deviations as this sample was not tested by a 
number of participants that did not obtain a 
presumptive resistant strain from this sample. 
All remaining samples had deviation levels 
below 5% (Figure 6). 
We did not perform analysis per laboratory as 
the performance on the AST depends on the 
isolation and on the number of strains tested 
and is therefore not suitable to compare 
different participants nor would give a realistic 
image on the participant’s capacity to perform 
the susceptibility testing which is analysed in 
the E. coli AST EQAS.  
 
Figure 4- Number of deviations per laboratory for isolation and identification of ESBL and or AmpC producing E. coli  
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Figure 3- Number of deviations per sample for isolation and identification of ESBL and or AmpC producing E. coli  
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3.3 ESBL /AmpC phenotypic testing 
conclusions 
Among the samples tested, the samples M-1.1, 
M-1.4 and M-1.7 contained ESBL producing 
strains carrying CTX-M genes (CTX-M-1, CTX-
M1 and CTX-M-9, respectively), whereas the 
samples M-1.2 and M-1.8 contained isolates 
with AmpC phenotypes (CMY-2 and 
chromosomal AmpC) and the remaining 
samples (M-1.3, M-1.5 and M-1.6) did not 
contain ESBL or AmpC presumptive isolates 
and were expected to be negative in the first 
part of the EQAS for the selective isolation. 
Due to the mixed phenotype obtained 
(essentially because of the cefoxitin resistance 
observed for the strain isolated from sample M 
1.1 and 1.4 and the variable cefepime result 
around the breakpoint for strain M-1.2), we 
have also determined that the option 
ESBL+pAmpC would be accepted as correct for 
the samples M-1.1, M-1.2 and M-1.4. 
In all, in 122 results uploaded, 113 were found 
correct (92.6%) and 9 (7.3%) were deviating. 
These deviations were mainly due to 
considering carbapenemase as a presumptive 
phenotype, based on finding the MIC to 
ertapenem above the breakpoint. This was the 
case for three deviations for lab #60, and one 
deviation each for lab# 42 and #56. 
Two deviations regarding the isolate obtained 
from sample M-1.8 were due to not classifying it 
as ESBL or AmpC (Lab #29 and #33), and one 
for the same sample was due to classifying it as 
presumptive ESBL (Lab #32). An additional 
deviation was related to the isolate from sample 
M-1.2 which was found as unusual phenotype 
by the participant from lab #26 as both 
cefepime and cefoxitin were found resistant.  
 
Figure 5- Number of deviations per antimicrobial for AST ESBL and or AmpC producing E. coli  
 
Figure 6- Number of deviations per sample for AST of ESBL and or AmpC producing E. coli  
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4. Discussion
4.1 ESBL and AmpC isolation and 
identification 
The 2015 EURL-AR matrix EQAS trial was the 
first of this kind and therefore it was a 
challenging exercise. The samples were 
prepared with strains selected beforehand for 
meat samples, but the caecal samples were not 
as straightforward and different approaches 
were used both with naturally positive samples 
and one spiked sample. The results were 
overall quite good, both regarding the 
isolation and AST parts, with expected 
negative and expected positive samples 
mostly well classified correct. However, there 
were issues related to the logistics with 
shipment that impeded two laboratories of 
having their results included in this report and 
among the samples sent, there were issues 
related with stability or possibly homogeneity 
of the contents regarding sample M-1.8 that 
might be deviations for a number of 
participants.  
4.2 Antimicrobial susceptibility 
testing 
The results uploaded were in general good, 
especially taking in account that they needed to 
retrieve the same isolate from the samples, 
were changes could have occurred (stability 
issues, conjugation into other strains, or 
plasmid losses). The range of uploaded results 
by the participating laboratories was very broad 
and some deviating results were caused by the 
different strains being obtained in the isolation 
procedures, than actual issues regarding the 
AST method. Therefore the analysis was not 
performed by laboratory. 
4.3 ESBL /AmpC phenotypic testing 
conclusions 
As what regards to the final conclusions for the 
AST testing and phenotypic confirmation, the 
conclusions depends heavily on the isolation 
process, thus some of the deviations might be 
related to the isolation of isolates that have 
different characteristics. However, we noticed 
that most deviations in this part were related to 
the interpretation of carbapenemase resistance, 
based on ertapenem results, which are very 
sensitive, but not very specific, leading to false 
classification as carbapenemase producers. 
Also some deviations were observed due to the 
difficulty in fitting in some of the isolates, due to 
results that lead to unusual phenotypes as 
cefepime might not fit into the classification 
scheme in some cases. 
5. Conclusion 
In general, the results of the first matrix EQAS 
demonstrate that most participating labs have 
set up the methods and are able to isolate 
ESBL and AmpC carrying strains from meat or 
caecal samples in a reliable fashion. There are, 
however still some MS that have issues with the 
methods, as all steps are relevant for the final 
result. One of the issues is the need to strictly 
control the conditions of the selective isolation 
procedure to select ESBL and AmpC E. coli and 
to do species identification with reliable 
methods to allow to detect all relevant isolates 
and assure that the species is correctly 
identified. 
The susceptibility testing results were in general 
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good, however a larger number of deviations 
were observed than in other AST EQAS and 
this might be related with the fact that the 
results of AST being dependent on the 
performance in the first part with isolation of 
the expected isolates (spiked or natural), 
which will be highly affected by testing 
different isolates or isolates that could have 
been modified in the sample (plasmid 
transfers or losses, etc). 
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Appendix 1- EURL-AR EQAS pre-notification 
G00-06-001/01.12.2014 
 
EQAS 2015 FOR SELECTIVE ISOLATION OF E. COLI WITH PRESUMPTIVE ESBL OR 
AMPC PHENOTYPES FROM MEAT OR CEACAL SAMPLES 
The EURL-AR announces the launch of another EQAS, thus providing the opportunity for 
proficiency testing which is considered an essential tool for the generation of reliable laboratory 
results of consistently good quality. 
This EQAS consists of testing of eight samples for selective isolation of  ESBL or AmpC 
presumptive E. coli. 
This EQAS is specifically for NRL’s on antimicrobial resistance involved in the monitoring 
according to the EU Commission legislation 652/2013 and specifically processing meat and faecal 
samples in the specific monitoring for ESBL implemented in 2015. Previously to this 
prenotification, the laboratories designated to be NRL-AR have been contacted to confirm the 
addresses for the shipment of these samples. Participation is free of charge for all above-mentioned 
designated laboratories.  
TO AVOID DELAY IN SHIPPING THE ISOLATES TO YOUR LABORATORY 
The content of the parcel is “UN3373, Biological Substance Category B”: Eight samples which 
might contain ESBL or AmpC producing E. coli included in a matrix of meat and/or ceacal sample 
will be shipped. Please provide the EQAS coordinator with documents or other information that can 
simplify customs procedures (e.g. specific text that should be written on the proforma invoice). To 
avoid delays, we kindly ask you to send this information already at this stage.  
TIMELINE FOR RESULTS TO BE RETURNED TO THE NATIONAL FOOD INSTITUTE 
Shipment of isolates and protocol: The isolates are expected to be shipped in the first week of 
November. The protocol for this proficiency test will be available for download from the website 
(www.eurl-ar.eu).  
Submission of results: Results must be submitted to the National Food Institute no later than 
December, 4, 2015  via a password-protected website. Upon reaching the deadline, each 
participating laboratory is kindly asked to enter the password-protected website once again to 
download an automatically generated evaluation report. 
EQAS report: A report summarising and comparing results from all participants will be issued. In 
the report, laboratories will be presented coded, which ensures full anonymity. The EURL-AR and 
the EU Commission, only, will have access to un-coded results. The report will be publicly 
available. 
 
Next EQAS: The next EURL-AR EQAS that we will have is on antimicrobial susceptibility testing 
of E. coli, staphylococci and enterococci which will be carried out in June, 2015.  
Please contact me if you have comments or questions regarding the EQAS. 
Sincerely, 
Lina Cavaco 
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Appendix 2- List of participants 
Institute  Country  Meat  Caecal 
Austrian Agency for Health and Food Safety  Austria  x  x 
Institute of Public Health  Belgium  x  x 
Veterinary Agrochemical Research center  Belgium    x 
National Centre of Food Safety, NRL "Salmonella, Campylobacter, 
Staphylococci and Antimicrobial Resistance"  Bulgaria  x  x 
Croatian Veterinary Institut  Croatia  x  x 
Veterinary Services  Cyprus  x  x 
State Veterinary Institute Praha  Czech Republic  x  x 
Danish Veterinary and Food Administration, DVFA  Denmark  x  x 
Estonian Veterinary and Food Laboratory  Estonia  x  x 
Finnish Food Safety Authority EVIRA  Finland  x  x 
ANSES ‐ Laboratoire de Fougères LERMVD  France (CAECAL)    x 
ANSES ‐ Laboratoire de sécurité alimentaire (LSAL) Maisons Alfort LERQAP  France (MEAT)  x   
Federal Institute for Risk Assessment  Germany  x  x 
Veterinary Laboratory of Chalkis  Greece  x  x 
Central Agricultural Office Veterinary Diagnostic Directorate  Hungary  x  x 
Institute For Experimental Pathology, University of Iceland, KELDUR  Iceland  x  x 
Central Veterinary Research Laboratory  Ireland  x  x 
Istituto Zooprofilattico Sperimentale delle Regioni Lazio e Toscana  Italy  x  x 
Institute of Food Safety, Animal Health and Environment "BIOR"  Latvia  x  x 
National Food and Veterinary Risk Assessment Institute  Lithuania  x  x 
Laboratoire de Medecine Vétérinaire  Luxembourg  x  x 
Public Health Laboratory  Malta  x  x 
Central Veterinary Institute of Wageningen UR  Netherlands  x  x 
Veterinærinstituttet  Norway  x  x 
National Veterinary Research Institute  Poland  x  x 
Laboratorio National de Investigacáo Veterinaria  Portugal  x  x 
Institute for Diagnosis and Animal Health  Romania  x  x 
State Veterinary and Food Institute  (SVFI)  Slovakia  x  x 
National Veterinary Institute  Slovenia  x  x 
Laboratorio Central de Sanidad, Animal de Algete  Spain    x 
VISAVET Health Surveillance Center, Complutense University  Spain  x  x 
Centro Nacional de Alimentación (AECOSAN)  Spain  x   
National Veterinary Institute, SVA  Sweden  x  x 
Vetsuisse faculty Bern, Institute of veterinary bacteriology  Switzerland  x  x 
Animal and Plant Health Agency (APHA)  United Kingdom  x  x 
 
NRL's   
Non‐NRL enrolled for EQAS  
Not EU‐member state   
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Appendix 3- Expected results for the matrix trial 
Qualitative results  
 
 Meat 
Sample  Gene background  Expected results selection isolation CFU per 25 g  CFU/g meat 
EURL‐M‐1.1  CTX‐M‐1  Positive  2.5 × 104  1 × 103 
EURL‐M‐1.2  CMY‐2  Positive  2.5 × 104  1 × 103 
EURL‐M‐1.3  None  Negative  0  0 
EURL‐M‐1.4  CTX‐M‐1  Positive  2.5 × 102  10 
EURL‐M‐1.5  ATCC  Negative  2.5 × 104  1 × 103 
 
 
Caecal 
Sample  Sample origin  Expected results selection isolation  CFU/g caecal sample 
EURL‐M‐1.6  Negative caecal sample  Negative  0 
EURL‐M‐1.7  Spiked high level with pig strain   Positive  1 × 105 
EURL‐M‐1.8  Naturally positive  Positive  1.5 × 102 
 
  
Appendix 3 
Page 2 of 3 
 
 
 
Susceptibility testing 
 
MIC- values and interpretations 
 
Panel 1 
Strain nr  Species  MERO  COL  AMP  AZI  TAZ  CHL  CIP  FOT  GEN  NAL  SMX  TET  TMP  TGC 
EURL‐M‐1.1  E. coli  <=0.03  <=1  >64  16  4  16  0,5  >4  2  128  >1024  >64  >32  1 
EURL‐M‐1.2  E. coli  <=0.03  <=1  >64  4  8  <=8  0.03  >4  1  <=4  <=8  <=2  <=0.25  <=0.25 
EURL‐M‐1.4  E. coli  <=0.03  <=1  >64  16  4  16  0.5  >4  2  128  >1024  >64  >32  1 
EURL‐M‐1.7  E. coli  <=0,03  <=1  >64  >64  0.5  >128  >8  >4  1  >128  >1024  >64  >32  <=0.25 
EURL‐M‐1.8  E. coli  <=0.03  <=1  >64  8  8  <=8  0.03  4  2  <=4  16  <=2  <=0.25  <=0.25 
 
Strain nr  Species  MERO  COL  AMP  AZI  TAZ  CHL  CIP  FOT  GEN  NAL  SMX  TET  TMP  TGC 
EURL‐M‐1.1  E. coli  S  S  R  S  R  S  R  R  S  R  R  R  R  S 
EURL‐M‐1.2  E. coli  S  S  R  S  R  S  S  R  S  S  S  S  S  S 
EURL‐M‐1.4  E. coli  S  S  R  S  R  S  R  R  S  R  R  R  R  S 
EURL‐M‐1.7  E. coli  S  S  R  R  S  R  R  R  S  R  R  R  R  S 
EURL‐M‐1.8  E. coli  S  S  R  S  R  S  S  R  S  S  S  S  S  S 
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 Panel 2 
Strain nr  Species  MERO  FEP  FOX  TAZ  FOT  T/C  F/C  IMI  ETP  TRM  ESBL conclusion 
EURL‐M‐1.1 E. coli <=0.03  16  16 4 64 0.25 0.12 <=0.12 0.06 16 ESBL or ESBL+pAmpC
EURL‐M‐1.2 E. coli <=0.03  0.25  64 8 8 4 8 0.25 0.12 16 AmpC or ESBL or ESBL+pAmpC
EURL‐M‐1.4 E. coli <=0.03  16  16 4 64 0.25 0.12 <=0.12 0.06 16 ESBL or ESBL+pAmpC
EURL‐M‐1.7 E. coli <=0.03  4  8 0,5 32 0.12 0.06 0.25 <=0.015 8 ESBL
EURL‐M‐1.8 E. coli <=0.03  0.12  >64 8 4 8 2 0.25 0.03 16 AmpC
 
Strain nr  Species  MERO  FEP  FOX  TAZ  FOT  T/C  F/C  IMI  ETP  TRM 
EURL‐M‐1.1 E. coli S  R  R R R NA NA S  S NA
EURL‐M‐1.2 E. coli S  R  R R R NA NA S  R NA
EURL‐M‐1.4 E. coli S  R  R R R NA NA S  S NA
EURL‐M‐1.7 E. coli S  R  S S R NA NA S  S NA
EURL‐M‐1.8 E. coli S  S  R R R NA NA S  S NA
 
   Resistant 
 NA   Not applicable or not testet 
Abbreviations: AMP ‐ ampicillin, AZI ‐ Azithromycicn, CHL ‐ chloramphenicol, CIP ‐ ciprofloxacin, COL ‐ colistin, ETP ‐ ertapenem, FEP ‐ cefepime,  FOT‐ cefotaxime, FOT/CLA 
‐ cefotaxime/clavulanic acid, GEN‐ gentamicin, IMI ‐ imipenem, MER‐ meropenem, NAL ‐ nalidixic acid, SMX ‐ sulphametoxazole, TAZ ‐ ceftazidime, TAZ/CLA ‐ 
ceftazidime/clavulanic acid, TET ‐ tetracycline, TMP ‐ trimethoprim, TGC ‐ tigecycline, TRM ‐ temocillin. 
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PROTOCOL  
For selective isolation of presumptive ESBL/AmpC producing Escherichia coli from meat 
and caecal samples (matrix EQAS) 
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1 INTRODUCTION 
The organisation and implementation of an External Quality Assurance System (EQAS) on 
selective isolation of presumptive ESBL/AmpC E. coli is among the tasks of the EU Reference 
Laboratory for Antimicrobial Resistance (EURL-AR), and will include the selective isolation 
procedures and AST of obtained isolates of eight samples of either meat or caecal content. In 2015, 
these eight samples will include five samples of 25g meat from bovine origin and three samples of 
1g of caecal content of porcine origin. These samples may contain (or not) E. coli presumptive of 
producing either ESBL or AmpC enzymes.  
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It is expected that the participating laboratories use in the analyses the same procedures used in the 
monitoring described by the regulation 652/2013, and perform the selective isolation and following 
the EU recommended methods published on the EURL-AR website www.eurl-ar.eu).  
2 OBJECTIVES 
This EQAS aims to support laboratories to assess and, if necessary, to improve the quality of results 
obtained in the selective isolation of presumptive ESBL and AmpC isolates from meat and caecal 
samples. Further objectives are to evaluate and improve the comparability of surveillance data on 
ESBL or AmpC producing of E. coli reported to EFSA by different laboratories. 
3 OUTLINE OF THE EQAS ON SELECTIVE ISOLATION OF PRESUMPTIVE ESBL 
AND AMPC ISOLATES FROM MEAT AND CAECAL SAMPLES (MATRIX EQAS) 
2015 
Shipping, receipt and storage of samples 
In November 2015, the National Reference Laboratories for Antimicrobial Resistance (NRL-AR) 
will receive a parcel containing eight samples from the National Food Institute. All strains used in 
the spiking of samples belong to UN3373, Biological substance, category B. Participants should 
expect that extended spectrum beta-lactamase (ESBL)-producing strains as well as AmpC-
producing  strains will be included in some of the sample matrix.  
The samples will be either 25g of meat (spiked matrix) or 1g of caecal content and will be 
distributed already weighed and ready to be tested, in tubes labelled from 1.1 to 1.8 (1.1 to 1.5 
being samples with 25g meat and 1.6 to 1.8 being samples containing 1g each of  caecal content) 
The samples will be shipped in frozen state in tubes and contained in cooling boxes with 
temperature control devices and cooling elements.  
Upon reception it is very important to open the parcel as soon as possible and proceed to the 
analysis (following the normal procedures for sample testing in the monitoring). It is required that 
participants:  
- When opening the parcel, note the date and exact time at opening (this data is very 
important to follow the temperature data checks).  
- Proceed to sample analysis immediately after opening the parcel 
- Register the date for analysis start for each sample 
- Collect the temperature control device (small discoid device located in a bag inserted in 
a labelled tube, located inside the parcel). Open the tube and take out the bag with the 
device inside. Place this bag with the device in the labelled bubble envelope provided and 
send it back to the EURL-AR as soon as possible. Please note that you will have to arrange 
for stamps/postage ( this could not be paid from the EURL-AR beforehand as you will have 
to dispatch it from your country and the post systems differ).   
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Selective isolation of ESBL or AmpC E. coli from the samples  
The samples provided in each parcel are weighed beforehand and therefore no further weighing is 
required. Proceed immediately to the first enrichment step by adding the sample to the necessary 
amount of media (225 ml of Buffered Peptone water for the meat samples and 9 ml for the caecal 
samples as referred in the official EURL-AR protocols. All the following procedures should follow 
the methods used in the monitoring for ESBL and AmpC E. coli according to the EC 652/2013 
regulation. If any changes are introduced to the official protocols these changes should be described 
with details in the online database on the methods upload page. The participants are responsible for 
assuring the validity of the plates and therefore the protocol for “Validation of selective MacConkey 
agar plates supplemented with 1 mg/L cefotaxime for monitoring of ESBL and AmpC producing E. 
coli in meat and animals” should be run beforehand as stated on the EURL-AR webpage http://eurl-
ar.eu/data/images/protocols/protocol_for_validation_of_macconkey_and_ctx_agarplates_nov2014.p
df. 
This EQAS does NOT focus on the specific isolation of E. coli producing carbapenemase enzymes, 
and therefore it is not needed to plate on the additional carbapenemase selective plates. 
Links to the officially recommended protocols: 
 For meat (to follow when testing samples 1.1 to 1.5):  
http://eurl-ar.eu/data/images/protocols/esbl_ampc_cpeprotocol_version_meat_dec2014_version2.pdf 
 
 For caecal content (to follow when testing samples 1.6 to 1.8): 
http://eurl-ar.eu/data/images/protocols/esbl_ampc_cpeprotocol_version_caecal_dec2014_version2.pdf 
 
As referred in these protocols the isolates obtained from isolation procedure should be identified as 
E. coli using the procedures for E. coli species identification applied at the participant’s laboratory 
for the specific monitoring of ESBL and AmpC producing E.coli. 
Please store the isolates obtained in the isolation procedure and document the whole process and all 
the findings in each step. As part of the submission, you will be requested to describe the findings 
along the enrichment process and selective isolation including to growth in the media, isolation of 
suspected colonies, species identification results and finally regarding the finding (or not) of 
presumptive E. coli isolates harbouring one of the selected resistances (this result will be evaluated 
in relation to the expected result as a qualitative result) (see details in the Testform).  
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Antimicrobial susceptibility testing 
If the sample is deemed positive for ESBL or AmpC producing E. coli, one E. coli isolate per 
sample should be taken further and tested for susceptibility to the antimicrobials as stated in the EU 
regulation (antimicrobials listed in Tables 1 and 2), using a two-step approach using both testing 
panels.  
The testing should be performed using the same method as implemented in your laboratory for 
performing AST when monitoring for EFSA according to the regulation EC 652/2013 and applying 
the interpretative criteria listed below.  
 
 
Table 1: Antimicrobials recommended for AST of Escherichia coli and interpretative criteria 
according to table 1 in EC regulation 652/2013 
 
Antimicrobials for E. coli MIC (g/mL) R is > 
Ampicillin, AMP 8 
Azithromycin, AZI 16*
Cefotaxime, FOT 0.25  
Ceftazidime, TAZ 0.5  
Chloramphenicol, CHL 16 
Ciprofloxacin, CIP 0.06  
Colistin, COL 2 
Gentamicin, GEN 2 
Meropenem, MERO 0.125 
Nalidixic acid, NAL 16 
Sulfamethoxazole, SMX 64 
Tetracycline, TET 8 
Tigecycline, TGC 1 
Trimethoprim, TMP 2 
* Tentative ECOFF established from EFSA data. 
 
Beta-lactam resistance 
Confirmatory tests for ESBL production are mandatory on all strains resistant to cefotaxime 
(FOT), ceftazidime (TAZ) or meropenem and should be performed by testing the second panel of 
antimicrobials (Table 2 in this document corresponding to Table 4 in EC regulation 652/2013). 
When submitting results to the database, please confirm for each sample if the second panel was 
included in the test. 
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Table 2: Antimicrobials recommended for additional AST of Escherichia coli resistant to 
cefotaxime, ceftazidime or meropenem and interpretative criteria according to table 4 in EC 
regulation 652/2013 
Antimicrobials for E. coli MIC (g/mL) R is > 
Cefepime, FEP 0.125 
Cefotaxime, FOT  0.25 
Cefotaxime + clavulanic acid (F/C) Not applicable 
Cefoxitin, FOX 8 
Ceftazidime, TAZ 0.5 
Ceftazidime+ clavulanic acid (T/C) Not applicable 
Ertapenem, ETP 0.06 
Imipenem, IMI 0.5 
Meropenem, MERO 0.125 
Temocillin, TRM Not available* 
*Where no interpretative criteria are available, we request the participants upload the MIC value obtained, and do not 
select an interpretation. 
Confirmatory test for ESBL production requires use of both cefotaxime (FOT) and ceftazidime 
(TAZ) alone and in combination with a -lactamase inhibitor (clavulanic acid). Synergy is defined 
either as i) a ≥ 3 twofold concentration decrease in an MIC for either antimicrobial agent tested in 
combination with clavulanic acid vs. its MIC when tested alone (MIC FOT : FOT/CL or TAZ : 
TAZ/CL ratio  8) (CLSI M100 Table 2A; Enterobacteriaceae). The presence of synergy indicates 
ESBL production. Resistance to cefepime gives further indication of ESBL production, but is not 
essential. 
Confirmatory test for carbapenemase production requires the testing of meropenem (MERO).  
Detection of AmpC-type beta-lactamases can be performed by testing the bacterium for 
susceptibility to cefoxitin (FOX). Resistance to FOX could indicate the presence of an AmpC-type 
beta-lactamase, that may be verified by PCR and sequencing. 
The classification of the phenotypic results should be based on the most recent EFSA 
recommendations (EFSA 2012), indicating the strains as: 
 Presumptive ESBL: strains with positive synergy test, susceptible to cefoxitin and resistant 
to cefepime  
 Presumptive ESBL+pAmpC: strains with positive or negative synergy test, resistant to 
cefoxitin and resistant to cefepime 
 Presumptive pAmpC phenotype: strains with negative synergy test, resistant to cefoxitin and 
susceptible to cefepime 
 Presumptive carbapenemase phenotype: strain resistant to meropenem 
 Unusual phenotype: any other combinations 
(However we recommend that strains which show synergy with clavulanic acid for at least one of 
the third generation cephalosporins cefotaxime or ceftazidime should be considered ESBL, 
independently of the cefepime result) 
Appendix 4‐ Protocol 
Page 6 of 8 
Page 6 of 8 
  
 
4 REPORTING OF RESULTS AND EVALUATION 
Please write your results in the test forms, and enter your results into the interactive web database.  
 
4.1 General recommendations for data upload 
We recommend reading carefully the description reported in paragraph 5 before entering your 
results in the web database. Results must be submitted no later than 4th, December, 2015. After 
the deadline when all participants have uploaded results, you will be able to login to the database 
once again, and to view and print an automatically generated report evaluating your results. Results 
in agreement with the expected interpretation are categorised as ‘correct’, while results deviating 
from the expected interpretation are categorised as ‘incorrect’. 
If you experience difficulties in entering your results, please contact us directly.  
All results will be summarized in a report which will be publicly available. The data in the report 
will be presented with laboratory codes. A laboratory code is known to the individual laboratory, 
whereas the complete list of laboratories and their codes is confidential and known only to the 
EURL-AR and the EU Commission. All conclusions will be public. 
If you have questions, please do not hesitate to contact the EQAS Coordinator: 
Lina Cavaco 
National Food Institute 
Technical University of Denmark 
Søltofts Plads, Building 221, DK-2800 Lyngby 
Denmark 
Tel: +45 3588 6269 
Fax: +45 3588 6341 
E-mail: licav@food.dtu.dk 
 
5 HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE 
Please read carefully this paragraph before entering the web page. 
Remember that you need by your side the completed test forms and the breakpoint values you used.  
Enter the EURL-AR EQAS 2015 start web page (http://eurl.food.dtu.dk/matrix ), write your 
username and password in lower-cases and press enter. Your username and password are indicated 
in the Welcome letter following the samples. Do not hesitate to contact us if you experience 
problems with the login. 
You can browse back and forth by using the Home or back keys, but please remember to save your 
inputs before. 
5.1 Sample reception/ testing 
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Please fill in with information in relation to date and time (please note the exact time) and 
temperature at arrival of the parcel contents as measured by you (we will also check on the thermo-
loggers data after you send back the device. 
 
5.2 Selective enrichment methods 
Please fill in with the details of the methods use and insert any changes made to the official method 
 
5.3 Test results  
 
5.3.1 Selective enrichment of presumptive ESBL or AmpC producing E. coli 
Fill in the answers for the questions regarding the selective enrichment results along the process 
5.3.2 Species identification enrichment of presumptive ESBL or AmpC producing E. coli 
Please confirm the results and conclude if you found an E. coli presumptive of producing an ESBL 
AmpC gene in the sample (this conclusion will be evaluated). 
If you respond to this question indicating that you did not find a presumptive isolate to go further 
you are not expected to fill in the remaining questions. 
If your answer is yes, you are expected to fill in the MIC tables and final conclusion of the AST and 
confirmatory testing. 
 
5.3.3 AST of E. coli 
 
Please respond with basis on the first MIC panel results if the isolate fulfils the criteria to be tested 
on the second panel (confirmatory phenotypic testing) or not and fill in the results for the second 
panel in case you decide to do the confirmatory testing. 
 
Complete the fields related to the results obtained in the result tables. 
Click on “save” and then go back using the tab “home” and enter another test page to upload results  
In the data entry pages, enter the obtained values and the interpretation (R, resistant or S, 
susceptible) for each E. coli isolate. 
 
Remember to report also the conclusion of the ESBL phenotypic testing. 
If you did not test for susceptibility to a given antimicrobial, please leave the field empty. 
Click on “save“ and then go back using the tab “home” and enter another test page to upload 
results.  
Click on “save“. 
 
5.4 Finalizing data input, EQAS evaluation and approval of result upload 
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Review the input pages by browsing through the pages and make corrections if necessary. 
Remember to save a page if you make corrections. If you press home a page without saving 
changes, you will see an error screen. In this case, click on “save“ to save your results, browse back 
to the page and then continue. 
Please complete the evaluation form for the EQAS when you finalize the data input. You can find 
the tab on the Home page, on the tab “Evaluation” 
Before approving your input, please be sure that you have filled in all the relevant fields for the 
sample sheet, the methods and the test results for all samples tested because YOU CAN ONLY 
APPROVE ONCE!  The approval blocks your data entry in the interactive database. 
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Test forms  
Selective isolation of presumptive ESBL/AmpC producing Escherichia coli from 
meat and caecal samples (matrix EQAS) 
 
 
Username:       
 
Contact person:       
 
Country:       
 
Date for filling in test forms:       
 
 
SAMPLES 
 
Reception date and exact time of opening the parcel of the proficiency test samples at the 
laboratory:             (date and time is required) 
 
Temperature of the contents of the parcel at arrival:      °C 
 
 
How many samples did your laboratory process in 2015 for monitoring of ESBL/AmpC-detection in relation 
to EC/2013/652? (choose only one option) 
 less than 100 samples 
 101-200 
 201-300 
 301-400 
 401- 1000  
 more than 1000 
 
Which kind of samples did your laboratory process in 2015 for monitoring of ESBL/AmpC-detection in 
relation to EC/2013/652? (you may chose more than one option) 
  caecal, cattle 
  caecal, swine 
  meat, beef 
  meat, pork 
  other matrices  Specify:       
 
Any other comments:       
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TEST FORM – ESBL/AmpC methods                                                           
 
Question 1 
Method used for selective isolation of ESBL/AmpC in this EQAS 
 
With reference to the selective isolation procedure using the EURL recommended protocols that refer to 
EC/652/2013; 
 
 The protocol was used without modifications (please jump to question 2) 
 
 The protocol was used, however, the pre-enrichment was modified (please respond to question 1.1) 
 
 The protocol was used, however, the selective isolation procedures were modified (please respond to 
question 1.2) 
 
 The protocol was used, however, the incubation conditions in the selective plating were modified 
(please respond to question 1.3) 
  
Question 1.1 
If you modified the pre-enrichment, please indicate the differences introduced 
 
 Different sample amount (weight) used for the enrichment procedure:  
       g in meat samples 
       g for caecal samples 
  
 Different volume of enrichment in the isolation step:  
       mL for meat samples 
       mL for caecal samples 
  
 Different pre-enrichment medium:      
 
Different incubation conditions in pre-enrichment      °C/     h;  
  
 Please justify these changes:       
  
Question 1.2 
If you made changes in the selective isolation procedure, please indicate the differences introduced 
 
 Different sample amount (weight) used for the enrichment procedure:  
       g in meat samples 
       g for caecal samples 
 
 Different concentration of cefotaxime:       mg/L 
  
 Different antimicrobial               
  
 Different medium       
      
 Please justify these changes:       
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Question 1.3 
If you used different incubation conditions in the selective plating, please indicate the differences introduced 
 
Please indicate the conditions used:      °C/     h;  
   
 Please justify these changes:       
  
Question 2 
Method used for confirmation of E. coli species identification. Please indicate the primary E. coli 
identification method used (choose only one option; if you used more than one method, please explain in the 
comments field) 
 
 PCR, using published methods 
 PCR, using in-house method 
  Biochemical tests 
  Maldi-Tof  
  DNA sequencing  
Comments:       
  
Question 3 
Method used for general antimicrobial susceptibility testing of the strains (choose only one option) 
 
 Microbroth dilution test on EUVSEC panel  
 Microbroth dilution test on another panel  
 Agar dilution method 
  E-test 
  Disk diffusion test 
  
Question 4 
Method used for phenotypic confirmatory testing of ESBL/AmpC (choose only one option) 
 
 Microbroth dilution test on EUVSEC2 panel  
 Microbroth dilution test on another panel  
 Agar dilution method 
  E-test 
  Disk diffusion test 
  
Question 5 
Additional comments.  
 
Please describe and justify your choice if you modified something in relation to the method defined in 
EC/652/2013:       
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TEST FORM                                                            
Sample EURL M-1.X 
 
Date the isolation procedure was started:        
 
Please describe the results you have observed regarding this sample: 
 
Visible growth in pre-enrichment:  
 Yes / No  
 
Growth on ESBL/AmpC-selective plates: 
 Yes  / No  
 
Please describe the growth observed on ESBL/AmpC-selective plates? (choose only one option) 
 Mixed culture containing typical E. coli colonies 
 Mixed culture without typical E. coli colonies 
 Pure culture of typical E. coli colonies 
 Pure culture without typical E. coli colonies 
 No growth 
 
Results of species identification: (choose only one option) 
 No isolates tested, sample negative 
 Presumptive ESBL/AmpC isolate identified as E. coli  
Comments:       
 
If you have found a presumptive ESBL/AmpC-positive isolate, please insert the results of 
antimicrobial susceptibility testing for the selected E. coli isolate (only one E.coli isolate is expected to 
be tested and these results will be evaluated in our database against the expected results). 
 
Based on the results from the first AST panel, was the isolate found resistant to cefotaxime, ceftazidime or 
meropenem so that the second panel was tested? (please note this question will be compared to the expected 
results and evaluated by the database) 
Yes  / No  
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AST results   
 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
E. coli 
EURL M-1.X 
Ampicillin, AMP                         
Azithromycin, AZI                   
Cefotaxime, FOT                    
Ceftazidime, TAZ                    
Chloramphenicol, CHL                    
Ciprofloxacin CIP                         
Colistin, COL                   
Gentamicin, GEN                    
Meropenem, MERO                   
Nalidixic acid, NAL                    
Sulfamethoxazole, SMX                   
Tetracycline, TET                    
Tigecycline, TGC                   
Trimethoprim, TMP                    
 
Second E. coli AST panel (ESBL/AmpC confirmatory testing)                                         
 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
E. coli 
EURL M-1.X 
Cefepime, FEP                   
Cefotaxime+clavulanic acid (F/C)                   
Cefotaxime, FOT                   
Cefoxitin, FOX                   
Ceftazidime, TAZ                   
Ceftazidime+clavulanic acid (T/C)                   
Ertapenem, ETP                   
Imipenem, IMI                   
Meropenem, MERO                   
Temocillin, TRM                   
Conclusions of confirmatory phenotypic testing: (choose only one option and please note that the final 
result will be evaluated by the database) 
 
 Presumptive ESBL 
 Presumptive ESBL+ pAmpC 
 Presumptive pAmpC 
 Presumptive carbapenemase 
 
 Unusual phenotype 
 No ESBL, AmpC or carbapenemase 
 
Comments (include optional genotype or other results):       
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